不可逆电穿孔治疗不可切除结直肠肝转移:COLDFIRE-2 Ⅱ期两中心单臂临床试验
COLDFIRE-2 为Ⅱ期两中心单臂试验,纳入 51 例因邻近关键结构或系统治疗受限而不适合切除或热消融的 18F-FDG PET 阳性结直肠肝转移患者,行经皮或开腹不可逆电穿孔。1 年无局部进展生存率 68%(95%CI:59, 84),达到主要终点;总体生存中位数 2.7 年,并发症率 40%,1 例(2%)90 天内死亡。
要点
- ≤5.0 cm 且邻近血管或胆管、不适合切除或热消融的结直肠肝转移可考虑 IRE。
- 1 年无局部进展生存率 68%(95%CI:59, 84),重复治疗后局部控制率 74%。
- 并发症率 40%,1 例(2%)因感染性胆汁瘤于术后 90 天内死亡(5 级不良事件)。
关键影像表现/征象
- 纳入标准为 18F-FDG PET 阳性的结直肠肝转移,肿瘤 ≤5.0 cm,不适合部分肝切除和热消融。
- 50 例共 76 个病灶(中位 2.2 cm,范围 0.5–5.4 cm)经 62 次操作成功完成 IRE;1 例因脉冲诱发心律失常提前终止。
- 局部控制允许重复操作,重复治疗后 74%(37/50)患者达到局部控制。
诊断标准与关键数值
- 主要终点为 1 年无局部进展生存率,竞争风险分析为 68%(95%CI:59, 84),需 ≥50% 方达标。
- 局部进展定义为治疗后局部肿瘤进展(LTP)。
- 中位总生存期自首次 IRE 起为 2.7 年(95%CI:1.6, 3.8)。
- 62 次操作中 25 次发生 34 例不良事件,总并发症率 40%;1 例(2%)90 天内死亡(5 级)。
临床应用与阅片要点
- 适用于因邻近血管、胆管等关键结构而不适合部分肝切除或热消融的 ≤5.0 cm 结直肠肝转移。
- 治疗前需 18F-FDG PET/CT 确认病灶代谢活性,随访结合肿瘤标志物与 18F-FDG PET/CT。
- 脉冲可能诱发心律失常,1 例因此提前终止操作,需术中监测。
- 局部进展后可重复 IRE,重复治疗后局部控制率 74%。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Irreversible electroporation (IRE), an ablative technique that uses high-voltage electrical pulses, has shown promise for eradicating tumors near critical structures, including blood vessels and bile ducts. Purpose To investigate the efficacy and safety of IRE for colorectal liver metastases (CRLMs) unsuitable for resection or thermal ablation because of proximity to critical structures and for further systemically administered treatments. Materials and Methods Between June 2014 and November 2018, participants with fluorine 18 (18F) fluorodeoxyglucose (FDG) PET-avid CRLMs measuring 5.0 cm or smaller, unsuitable for partial hepatectomy and thermal ablation, underwent percutaneous or open IRE (ClinicalTrials.gov identifier: NCT02082782). Follow-up included tumor marker assessment and 18F-FDG PET/CT imaging. For the primary end point to be met, at least 50% of treated participants had to be alive without local tumor progression (LTP) at 12 months, defined as LTP-free survival. Secondary aims were safety, technical success, local control allowing for repeat procedures, disease-free status, and overall survival. Results A total of 51 participants (median age, 67 years [interquartile range, 62-75 years]; 37 men) underwent IRE. Of these 51 participants, 50 with a total of 76 CRLMs (median tumor size, 2.2 cm; range, 0.5-5.4 cm) were successfully treated in 62 procedures; in one participant, treatment was stopped prematurely because of pulse-induced cardiac arrhythmia. With a per-participant 1-year LTP-free survival of 68% (95% CI: 59, 84) according to competing risk analysis, the primary end point was met. Local control following repeat procedures was achieved in 74% of participants (37 of 50). Median overall survival from first IRE was 2.7 years (95% CI: 1.6, 3.8). Twenty-three participants experienced a total of 34 adverse events in 25 of the 62 procedures (overall complication rate, 40%). One participant (2%), who had an infected biloma after IRE, died fewer than 90 days after the procedure (grade 5 adverse event). Conclusion Irreversible electroporation was effective and relatively safe for colorectal liver metastases 5.0 cm or smaller that were unsuitable for partial hepatectomy, thermal ablation, or further systemic treatment. © RSNA, 2021 Online supplemental material is available for this article. See also the editorial by Goldberg in this issue.
引用
- Meijerink MR, Ruarus AH, Vroomen LGPH, et al. Irreversible Electroporation to Treat Unresectable Colorectal Liver Metastases (COLDFIRE-2): A Phase II, Two-Center, Single-Arm Clinical Trial. Radiology. 2021. PMID: 33724066. doi:10.1148/radiol.2021203089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。